Vanda Pharmaceuticals
VNDA
164 hedge funds and large institutions have $524M invested in Vanda Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 60 increasing their positions, 55 reducing their positions, and 22 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 55
0% more funds holding
Funds holding: 164 → 164 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 22
1.61% less ownership
Funds ownership: 101.12% → 99.51% (-1.6%)
17% less capital invested
Capital invested by funds: $631M → $524M (-$107M)
60% less call options, than puts
Call options by funds: $1.08M | Put options by funds: $2.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$6.95M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.79M |
| 3 |
SG Americas Securities
New York
|
+$3.05M |
| 4 |
Goldman Sachs
New York
|
+$2.97M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$2.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$15.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.98M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$3.42M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$3.37M |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$3.29M |
VNDA Hedge Fund Activity: Q3 2020 in Review
164 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2020, worth a combined $524M — down 17% from $631M a quarter earlier.
Fund positioning in VNDA was balanced in Q3 2020: 22 funds opened new positions, 22 closed out, 60 added to existing stakes and 55 trimmed.
The largest buyer was Armistice Capital, adding an estimated $6.95M. The largest seller was Invesco, cutting an estimated $15.4M.
- 164 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $524M of Vanda Pharmaceuticals stock for Q3 2020, down 17% quarter-over-quarter.
- 22 funds opened new Vanda Pharmaceuticals positions in Q3 2020 and 22 closed out, a net change of 0 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2020 was Armistice Capital, an estimated $6.95M added.
- The largest Vanda Pharmaceuticals seller in Q3 2020 was Invesco, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2020.